Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) announced expanded clinical progress across the United States on Feb 25, 2026, supporting its strategy to grow U.S. adoption of minimally invasive microwave ablation (MWA) for benign thyroid conditions.

Clinical use by Samer Nakhle, M.D., in Las Vegas and Sophie Dream, M.D., at UAB are cited as milestones reinforcing commercial rollout and broader physician access, with US CEO Mark Saxton saying the integrations validate the company’s commercial roadmap.

News Market Reaction – BDMD

+28.96%

35 alerts

+28.96% News Effect

+23.6% Peak in 5 hr 46 min

+$20M Valuation Impact

$87M Market Cap

0.8x Rel. Volume

On the day this news was published, BDMD gained 28.96%, reflecting a significant positive market reaction. Argus tracked a peak move of +23.6% during that session. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $20M to the company's valuation, bringing the market cap to $87M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $2.36 Vol: Volume 2,339,271 is 0.58x...

low vol

$2.36 Last Close

Volume Volume 2,339,271 is 0.58x the 20-day average of 4,056,896, suggesting no unusual trading surge pre-news. low

Technical Price at $1.83 trades below the 200-day MA of $2.40 and sits 74.8% under the 52-week high $7.2616.

Peers on Argus

BDMD showed a positive move of 7.65% while scanner momentum flagged only RCEL mo...

1 Down

BDMD showed a positive move of 7.65% while scanner momentum flagged only RCEL moving down 3.01%. Core device peers showed mixed single-digit moves, pointing to stock-specific dynamics rather than a broad medical device rotation.

Historical Context

5 past events · Latest: Feb 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Conference showcase	Positive	+5.6%	Planned U.S. conference demos to promote MWA thyroid solutions.
Feb 11	U.S. commercial launch	Positive	-7.6%	Commercial launch at Bakersfield Memorial Hospital for benign thyroid tumors.
Feb 09	Education initiatives	Positive	+9.7%	Clinical education programs in the U.S. and Japan for MWA adoption.
Jan 28	Gynecology masterclass	Positive	+6.9%	Gynecological MWA masterclass in Shanghai to train physicians in Asia.
Jan 26	Strategic partnership	Positive	+0.0%	Partnership with Stonewood Key Capital using Hainan Free Trade Port hub.

Pattern Detected

Commercial and education-focused updates have more often led to positive price reactions, with occasional negative or flat responses.

Recent Company History

Over the last month, BDMD has repeatedly highlighted expansion of its Microwave Ablation platform, from U.S. clinical conferences (Feb 27–28, Mar 6–7, Mar 11–13) to a commercial launch at Bakersfield Memorial Hospital on Feb 11, 2026. Additional initiatives included U.S. and Japan clinical education and a gynecology masterclass in Shanghai, plus a strategic partnership on Jan 26, 2026. Today’s announcement continues this theme of growing U.S. clinical adoption for benign thyroid applications.

Market Pulse Summary

The stock surged +29.0% in the session following this news. A strong positive reaction aligns with p...

Analysis

The stock surged +29.0% in the session following this news. A strong positive reaction aligns with prior BDMD news, where several commercial and education updates saw gains of up to 9.73%. The stock still traded 74.8% below its 52-week high, so investors previously focused on execution risk and overhangs. Reactions to similar announcements have not been uniformly positive, suggesting enthusiasm could fade if clinical adoption or capital-market risks highlighted in filings remain front of mind.

Key Terms

microwave ablation, interventional thyroidology, endocrine surgery

3 terms

microwave ablation medical

"a market leader in minimally invasive Microwave Ablation (MWA) technology"

Microwave ablation is a medical procedure that uses focused microwave energy to heat and destroy abnormal tissue, such as tumors, through a needle-like probe inserted into the body; think of it as using a tiny, targeted microwave oven to cook away problem cells without large incisions. It matters to investors because it represents a growing category of minimally invasive treatments that can reduce hospital stays, create demand for specialized devices and disposables, and influence reimbursement and adoption trends in healthcare markets.

interventional thyroidology medical

"Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology"

Interventional thyroidology is the medical field that treats thyroid problems using minimally invasive procedures—such as image-guided needle therapies, thermal or chemical ablation, and targeted drainages—instead of open surgery. For investors, it matters because these procedures drive demand for specialized devices, training, and outpatient services, can lower costs and recovery time for patients, and influence reimbursement and market growth for companies supplying the equipment and clinics.

endocrine surgery medical

"Chief of the Section of Endocrine Surgery at the University of Alabama"

Surgical procedures on the body's hormone-producing glands—most commonly the thyroid, parathyroid, adrenal glands and certain pancreas tumors—aimed at removing disease, correcting hormone imbalances or diagnosing conditions. For investors, endocrine surgery matters because it drives demand for specialized devices, imaging, hospital services and follow-up therapies; like repairing a malfunctioning thermostat in a house, successful surgery can restore balance and reduce long-term treatment costs, affecting healthcare revenues and reimbursement patterns.

AI-generated analysis. Not financial advice.

NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced new clinical progress across the United States. This momentum directly supports the Company's strategy to accelerate global growth and expand patient access to advanced, minimally invasive therapies.

Reinforcing the Company's market leadership in the western United States, Samer Nakhle, M.D., FACE, ECNU, Medical Director of Palm Medical Group in Las Vegas, Nevada, recently leveraged Baird Medical's technology for benign thyroid applications. His work secures broader adoption of these innovative treatments across diverse practice environments.

Sophie Dream, M.D., MPH, FACS, Associate Professor and Chief of the Section of Endocrine Surgery at the University of Alabama at Birmingham, drives this national momentum forward. She utilized Baird Medical's platforms to address benign thyroid conditions, empowering the broader medical community to adopt highly effective, tissue-sparing interventions.

"Integrating our systems into leading academic and private practices drives our core mission," stated Mark Saxton, US CEO of Baird Medical. "These recent milestones validate our commercial roadmap and ensure more physicians have the tools necessary to elevate patient care."

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-accelerates-us-expansion-in-interventional-thyroidology-302696713.html

SOURCE BDMD

FAQ

What clinical progress did Baird Medical (BDMD) announce on February 25, 2026?

Baird Medical reported expanded U.S. clinical use of its MWA systems for benign thyroid conditions. According to the company, physicians in Las Vegas and at UAB recently used its platforms, supporting broader adoption across academic and private practices.

How does the BDMD update affect physician access to microwave ablation for thyroid treatment?

The update signals expanded physician access to MWA technology for benign thyroid cases. According to the company, recent integrations into academic and private practices aim to make tissue-sparing interventions more widely available to clinicians and patients.

Which clinicians were named in Baird Medical's Feb 25, 2026 announcement for BDMD?

The announcement named Samer Nakhle, M.D., at Palm Medical Group and Sophie Dream, M.D., at University of Alabama at Birmingham. According to the company, both clinicians used BDMD systems to treat benign thyroid conditions in their practices.

Does Baird Medical (BDMD) claim this news validates its commercial roadmap?

Yes, the company said these clinical milestones validate its commercial roadmap and growth strategy. According to the company, integrating systems into leading practices supports accelerating U.S. expansion and broader patient access to MWA.

What does the Feb 25, 2026 BDMD news mean for patient access to minimally invasive thyroid therapies?

The news indicates potential broader patient access to minimally invasive MWA treatments for benign thyroid conditions. According to the company, recent clinical adoptions by academic and private physicians are intended to expand availability across diverse practice settings.